Stock Market Reviews

Read and share opinions on SVRA (Savara Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
  Dec 22, 2025
• Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
  Dec 17, 2025
• Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
  Dec 11, 2025
• Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
  Dec 2, 2025
• Savara (SVRA) Climbs 27.8% Ahead of 2 Health Conferences
  Dec 1, 2025
• Savara Announces Participation in Upcoming Investor Healthcare Conferences
  Nov 20, 2025
• Assessing Savara (SVRA) Valuation Following Recent Share Price Momentum
  Nov 14, 2025
• Savara Reports Third Quarter 2025 Financial Results and Provides Business Update
  Nov 12, 2025
• Savara Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M
  Oct 31, 2025
• What Does Wall Street Think About Savara Inc. (SVRA)?
  Oct 31, 2025
• Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants
  Oct 30, 2025
• Savara Announces Proposed Public Offering
  Oct 29, 2025
• Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
  Oct 29, 2025
• Savara Inc. (SVRA) To Present Molgramostim Data in the Fight Against Infections
  Oct 29, 2025
• Savara Announces Chief Medical Officer (CMO) Transition
  Oct 17, 2025
• Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025
  Oct 2, 2025

SVRA News

• Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
  LANGHORNE, Pa., December 22, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced today that it has resubmitted the MOLBREEVI BLA to the FDA, with Fujifilm as the drug substance manufacturer. The MOLBREEVI BLA submission is seeking approval for the treatment of autoimmune PAP, a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli. The Company has reques
  Dec 22, 2025
• Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
  LANGHORNE, Pa., December 17, 2025--Savara Inc. (Nasdaq: SVRA) (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will present and host one on one meetings at the 44th Annual J.P. Morgan Healthcare Conference.
  Dec 17, 2025
• 3 High Growth Tech Stocks To Watch In The US Market
  As the U.S. market grapples with fluctuating indices and AI bubble concerns, the Dow Jones Industrial Average recently hit an all-time high before retreating, while tech-heavy stocks like those in the Nasdaq face pressure amid broader economic uncertainties. In this dynamic environment, identifying high-growth tech stocks involves looking for companies that demonstrate resilience and adaptability to market shifts, particularly those that can navigate technological advancements and investor...
  Dec 15, 2025
• Savara (SVRA) Deepens Patent Moat for MOLBREEVI in Europe Is Its Rare-Disease Edge Widening?
  Savara Inc. recently reported that the European Patent Office intends to grant a patent covering the liquid formulation of MOLBREEVI, its orally inhaled recombinant human GM-CSF for treating autoimmune pulmonary alveolar proteinosis, with protection in Europe expected to extend through March 2041. This prospective patent, combined with MOLBREEVI’s multiple expedited and orphan designations across the U.S., EU, and U.K., reinforces the therapy’s potential exclusivity and competitive moat in a...
  Dec 11, 2025
• Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
  LANGHORNE, Pa., December 11, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the EPO notified the Company of its intention to grant a patent application covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF).
  Dec 11, 2025
• Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
  LANGHORNE, Pa., December 02, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the European Patent Office (EPO) has issued patent No. 4 496 611 titled, "Drug-Device Combination Comprising a Liquid Solution and a Nebulizer for Aerosolization of the Liquid Solution." The patent is jointly held by Savara and PARI and covers the combination of Savara’s investigational therapy, MOLBREEVI, and PARI’s investigation
  Dec 2, 2025
• Savara (SVRA) Climbs 27.8% Ahead of 2 Health Conferences
  We recently published 10 Small Caps With Big Double-Digit Gains. Savara Inc. (NASDAQ:SVRA) is one of the top performers of last week. Savara soared by 27.84 percent week-on-week, as investors positioned their portfolios ahead of business updates from its participation in two conferences this week. According to the company, members of its management team will […]
  Dec 1, 2025
• Savara Announces Participation in Upcoming Investor Healthcare Conferences
  LANGHORNE, Pa., November 20, 2025--Savara Inc. (Nasdaq: SVRA) (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host one on one meetings and participate in fireside chats at two upcoming healthcare conferences.
  Nov 20, 2025
• Exploring High Growth Tech Stocks in the US Market
  The U.S. stock market recently experienced a significant downturn, with major indices such as the Nasdaq and S&P 500 closing sharply lower, driven by a notable decline in technology shares. In this environment of heightened volatility and economic uncertainty, identifying high-growth tech stocks requires careful consideration of their potential for innovation and resilience amidst broader market fluctuations.
  Nov 14, 2025
• Assessing Savara (SVRA) Valuation Following Recent Share Price Momentum
  Savara (SVRA) stock has attracted attention recently, following a nearly 3% increase in a single day and a notable 40% gain over the past three months. Investors are watching to see if this momentum continues. See our latest analysis for Savara. Savara’s share price is building real momentum, with its latest 26% 1-month gain capping off a robust run and helping drive a 39% year-to-date price return. That said, the three-year total shareholder return of 225% shows this hasn’t just been a flash...
  Nov 14, 2025
• Savara Reports Third Quarter 2025 Financial Results and Provides Business Update
  LANGHORNE, Pa., November 12, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2025.
  Nov 12, 2025
• Savara Announces Participation in Upcoming Investor Healthcare Conferences
  LANGHORNE, Pa., November 03, 2025--Savara Inc. (Nasdaq: SVRA) (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and participate in fireside chats at two upcoming healthcare conferences.
  Nov 3, 2025
• What Does Wall Street Think About Savara Inc. (SVRA)?
  Savara Inc. (NASDAQ:SVRA) is one of the best stocks under $5 with highest upside potential. On October 23, Citizens JMP lifted its price target on Savara Inc. (NASDAQ:SVRA) to $11 from $8 while keeping an Outperform rating on the shares. The firm told investors in a research note that its pulmonologist survey shows solid demand […]
  Oct 31, 2025
• Savara Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M
  LANGHORNE, Pa., October 31, 2025--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the closing of its previously announced underwritten public offering of 28,452,381 shares of common stock, including 4,642,857 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at $4.20 per share. In addition, in lieu of shares of common stock, Savara sold to cer
  Oct 31, 2025
• Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants
  LANGHORNE, Pa., October 30, 2025--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten public offering of 23,809,524 shares of its common stock at a price of $4.20 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 7,142,857 shares of common stock at a price of $4.199 per pre-funded warrant, in each case, before deducting underwriting dis
  Oct 30, 2025
• October 2025 Penny Stocks With Growth Potential
  As of late October 2025, the U.S. stock market is experiencing mixed results, with Federal Reserve Chair Jerome Powell indicating uncertainty about a potential rate cut in December. In such a climate, investors might consider exploring penny stocks—companies that are often smaller or newer and can provide unique growth opportunities when supported by strong financials. These stocks may still hold relevance for those seeking to uncover promising investments beyond the well-known giants,...
  Oct 30, 2025
• Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
  LANGHORNE, Pa., October 29, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced a $75 million royalty funding agreement with funds managed by RTW Investments, LP (RTW), subject to FDA approval of MOLBREEVI.
  Oct 29, 2025
• Savara Inc. (SVRA) To Present Molgramostim Data in the Fight Against Infections
  Savara Inc. (NASDAQ:SVRA) is one of the top long-term biotechnology stocks to buy. On October 2, Savara Inc. (NASDAQ:SVRA) announced that its partner, TrilliumBiO, will present data on the development of a dried-serum assay at the upcoming CHEST 2025 conference. TrilliumBiO is developing a dried-serum assay to enhance the detection of GM-CSF antibodies and aid […]
  Oct 29, 2025
• Savara Announces Proposed Public Offering
  LANGHORNE, Pa., October 29, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed of
  Oct 29, 2025
• Savara Announces Chief Medical Officer (CMO) Transition
  LANGHORNE, Pa., October 17, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced Yasmine Wasfi, M.D., Ph.D., FCCP has been promoted to CMO, effective immediately. She succeeds Ray Pratt, M.D., FACP who will transition from his current role to Senior Medical Advisor. Dr. Wasfi will report directly to the Company’s Chair and Chief Executive Officer and will serve as a member of the executive leadership team
  Oct 17, 2025
• Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025
  LANGHORNE, Pa., October 02, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation and one abstract as an oral presentation at CHEST 2025 in Chicago, Illinois, October 19-22. The Company will also host a Learning Theatre titled "Advances in Autoimmune Pulmonary Alveolar Proteinosis" at the meeting which is open to all registered conference attendees.
  Oct 2, 2025
• Promising Penny Stocks To Consider In October 2025
  As the U.S. stock market continues its upward trajectory, with major indices like the S&P 500 and Dow Jones Industrial Average reaching new heights, investors are keenly watching for opportunities amidst potential economic uncertainties such as a looming government shutdown. Penny stocks, often representing smaller or newer companies, remain an intriguing area for those seeking growth at lower price points. Despite their vintage-sounding name, these stocks can offer significant upside when...
  Oct 1, 2025
• Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025
  LANGHORNE, Pa., September 29, 2025--Savara Inc. (the "Company") (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced additional analyses from its pivotal Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP were presented as poster presentations at the ERS Congress 2025 in Amsterdam, The Netherlands.
  Sep 29, 2025
• Guggenheim Lifts Savara (SVRA) Price Target on Pulmonary Alveolar Proteinosis Opportunity
  Savara Inc. (NASDAQ:SVRA) is one of the best healthcare penny stocks to buy now. On September 9, Guggenheim raised its price target of the stock to $11 from $8 while reiterating a Buy rating. The price target hike follows an impressive 16% stock rally year to date. The research firm raised its price target, buoyed […]
  Sep 20, 2025
• Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis
  LANGHORNE, Pa., September 02, 2025--Savara Inc. (the "Company") (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced an increased estimate of autoimmune PAP diagnosed prevalence in the U.S. The updated analysis indicates an ~50% larger autoimmune PAP patient population in the U.S. than the Company’s previously estimated claims analysis from 2023 (~5,500 autoimmune PAP patients versus ~3,600). The recent analysis of health claims data wa
  Sep 2, 2025
• Spotlight On Definitive Healthcare And 2 Other Promising Penny Stocks
  The U.S. stock market continues to break new ground, with the S&P 500 reaching record highs as investors anticipate major earnings reports and keep a close watch on Federal Reserve developments. In this context, penny stocks—often associated with smaller or newer companies—remain a relevant investment area despite their somewhat outdated label. When these stocks are backed by strong financials, they can offer significant growth opportunities at lower price points.
  Aug 28, 2025
• Savara Inc. (SVRA) Upgraded to Buy After FDA CMC Breakthrough
  Savara Inc. (NASDAQ:SVRA) is among the best US stocks under $10 to invest in. H.C. Wainwright has raised the price target on Savara Inc. (NASDAQ:SVRA) to $5.00 from $2.00, while upgrading the stock from Neutral to Buy. Much of this optimism is driven by the company’s agreement with the FDA on Chemistry, Manufacturing, and Controls […]
  Aug 23, 2025
• New England Journal of Medicine (NEJM) to Publish Results From Savara’s Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
  LANGHORNE, Pa., August 20, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that the results from the Phase 3 IMPALA-2 clinical trial will be published online in NEJM. The manuscript, titled "A Phase 3 Trial of Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis" will appear in the August 21, 2025, online version of the publication and can be found at www.nejm.org. Following the online
  Aug 20, 2025

SVRA Reviews

• CapitalHex

  Dec 30, 2025

  $SVRA This company is paving the way in the pharmaceutical sector with its innovative therapies targeting rare diseases. Their commitment to research and development showcases a forward-thinking approach that could position them favorably within the market.

  Buy

• TendieTitan

  Dec 30, 2025

  $SVRA This company is all about brave new medical adventures—let’s just hope they don’t call it a ‘science experiment’!

  Buy

• OptionOutlaw

  Dec 30, 2025

  $SVRA This one is about as exciting as watching paint dry.

  Sell

• DividendGhost

  Dec 30, 2025

  $SVRA With recent developments stirring up the market, it's hard to ignore the potential for rapid growth. It feels like a rollercoaster waiting to happen, with every twist and turn causing heart rates to spike!

  Buy

• BearishBoi

  Dec 29, 2025

  $SVRA Just when you thought it was safe to go back in the water, this company is making waves! Surf’s up for innovation!

  Buy

• TheChartCode

  Dec 29, 2025

  $SVRA This stock is like a rollercoaster with ups and downs, but hey, the thrill makes it worthwhile! 🎢🙌

  Sell

• BullRaid

  Dec 29, 2025

  $SVRA Another biotech dream that’s just a nightmare.

  Sell

• TradeReckoner

  Dec 28, 2025

  $SVRA Biotech stocks are just lottery tickets for the hopeful.

  Sell

• ProfitLancer

  Dec 28, 2025

  $SVRA Another biotech that can't seem to get off the ground.

  Sell

• GainMachine

  Dec 28, 2025

  $SVRA This biotech company is like a mad scientist, cooking up solutions that might just save the day!

  Buy

• ChartPhantom

  Dec 28, 2025

  $SVRA This biotech has the potential to cure more than just a Monday morning. Let's hope they work their magic!

  Buy

• BearFighter

  Dec 27, 2025

  $SVRA So underwhelming, even the competition might feel sorry.

  Sell

• WallStreetWolf

  Dec 27, 2025

  $SVRA This stock is like that one friend who's always got your back in a tough situation. Plus, they might have some cool science stuff happening!

  Buy

• BuyLowBro

  Dec 27, 2025

  $SVRA This one feels like the plot twist in a teen drama—unexpected, intriguing, but keep your popcorn handy!

  Buy

• ChartPhantom

  Dec 26, 2025

  $SVRA This stock is like a dog that fetches your slippers but sometimes brings back a squirrel. Kinda unpredictable!

  Sell

• YOLOTrader

  Dec 26, 2025

  $SVRA Imagine a superhero that keeps saving people but forgets to save itself. This stock might need a cape upgrade.

  Sell

• StonkPhantom

  Dec 26, 2025

  $SVRA The clinical trials are in, and the pressure is on! Every update feels like a rollercoaster—will it be thrilling success or gut-wrenching failure?

  Buy

• TradePredator

  Dec 26, 2025

  $SVRA Savara Inc. seems to be savaging any chance of success.

  Sell

• PriceBreaker

  Dec 26, 2025

  $SVRA This company's dedication to developing innovative therapies highlights its potential to make a significant impact in the healthcare sector. Their pipeline reflects a strong commitment to addressing unmet medical needs, which could translate into future success.

  Buy

• MarketSavage

  Dec 25, 2025

  $SVRA Hope you've got a strong stomach for this ride.

  Sell

• BearFighter

  Dec 24, 2025

  $SVRA Proving that not all innovation deserves applause.

  Sell

• ByteBull

  Dec 24, 2025

  $SVRA It’s like that friend who always wants to try new things—could be a hit or a total flop!

  Sell

• CryptoCobra

  Dec 23, 2025

  $SVRA This company is like that one kid who never gives up on their lemonade stand, even when it's raining money. Gotta respect the hustle!

  Sell

• CashCraze

  Dec 23, 2025

  $SVRA This biotech firm is advancing its pipeline with promising therapies that address significant unmet medical needs, showcasing strong potential for future growth.

  Buy

• WallStreetWolf

  Dec 22, 2025

  $SVRA This company's got more potential than my Wi-Fi during a Netflix binge! It’s all about that next episode of growth.

  Buy

• AlphaDruid

  Dec 22, 2025

  $SVRA With clinical trials constantly pushing boundaries and investors' hopes hanging by a thread, the volatility here can make your head spin! The potential is huge, but the stakes are incredibly high.

  Buy

• StockSpecter

  Dec 22, 2025

  $SVRA This one seems to be stuck in a perpetual loop of disappointment.

  Sell

• TheTradingVerse

  Dec 22, 2025

  $SVRA Engaged in the development of therapies for rare diseases, this company shows promise with its focused research efforts. The potential for breakthrough discoveries could position it favorably in the biotech sector.

  Buy

• FiscalBinary

  Dec 22, 2025

  $SVRA The volatility is intense! Investors are sweating bullets as they try to navigate through mixed signals in the market. It’s a tense game of chance that’s got everyone second-guessing their instincts.

  Sell

• MarketRender

  Dec 22, 2025

  $SVRA After a rollercoaster of clinical trials and market uncertainty, the stakes are higher than ever! Will they emerge victorious or fade into the background of the biotech scene?

  Sell

• YieldSlasher

  Dec 22, 2025

  $SVRA Chasing dreams like it’s a marathon — good luck.

  Sell

• CashKiller

  Dec 21, 2025

  $SVRA Another biotech with more hype than substance.

  Sell

• FiscalRogue

  Dec 21, 2025

  $SVRA A company that screams 'underperformer'; steer clear.

  Sell

• IndexPredator

  Dec 21, 2025

  $SVRA Biotech is a gamble; one breakthrough can mean the world, but will they strike gold or face another setback? The pressure is palpable.

  Buy

• DividendHunter

  Dec 21, 2025

  $SVRA If only potential could translate to performance.

  Sell

• HedgeMeNot

  Dec 20, 2025

  $SVRA Chillin' in that biotech zone, they might just surprise us all!

  Buy

• PortfolioPunk

  Dec 20, 2025

  $SVRA Chasing shadows in a market full of light.

  Sell

• FiscalFury

  Dec 20, 2025

  $SVRA They're trying to cure things, which is cool, but wouldn't it be great if they could also cure Mondays?

  Sell

• EquityPulse

  Dec 20, 2025

  $SVRA In an unpredictable healthcare landscape, this company is navigating treacherous waters. Will they find the breakthrough or get lost in the tide? Every moment counts!

  Buy

• LiquidLegend

  Dec 18, 2025

  $SVRA This company is working on turning tough conditions into smooth sailing—kind of like your friend trying to navigate a group project!

  Buy

• AlphaVandal

  Dec 17, 2025

  $SVRA Innovation? More like a long, tedious wait for something mediocre.

  Sell

• FiscalRiot

  Dec 17, 2025

  $SVRA The volatility in this biotech field is heart-stopping! Each update sends shockwaves through the community—can it defy the odds and prove skeptics wrong?

  Buy

• ProfitGremlin

  Dec 16, 2025

  $SVRA Got that fresh approach, making waves in the health scene!

  Buy

• ChartSaber

  Dec 16, 2025

  $SVRA A bit of a sleeper, could wake up and surprise everyone soon.

  Buy

• FiscalFury

  Dec 16, 2025

  $SVRA Like a magician pulling rabbits from hats, they're conjuring up new treatments out of thin air—abracadabra, indeed!

  Buy

• ChartFang

  Dec 15, 2025

  $SVRA This biotech company is making strides in addressing unmet medical needs, highlighting its potential for breakthroughs. Its ongoing research initiatives could attract attention from investors looking for high-reward opportunities.

  Buy

• YieldHunter

  Dec 15, 2025

  $SVRA Dedicated to addressing unmet medical needs, this company is making meaningful strides in research and development that could lead to major advancements in patient care, highlighting its potential for growth.

  Buy

• FiscalFrost

  Dec 15, 2025

  $SVRA Focusing on rare diseases, this firm is tackling significant medical challenges with its cutting-edge research. Their pipeline’s potential, coupled with recent advancements, underlines a strong commitment to transforming treatment options.

  Buy

• ChartNomad

  Dec 14, 2025

  $SVRA With a promising pipeline and strategic focus, this one could skyrocket or plummet! Keep a close eye on the upcoming earnings report; volatility is bound to keep you on edge!

  Buy

• AlphaWave

  Dec 14, 2025

  $SVRA This stock is trying to carve out its niche in a crowded biotech field, but with so much at stake, every trial result is a nail-biter—will it rise or fall spectacularly?

  Sell

• BearMarketSurvivor

  Dec 14, 2025

  $SVRA Momentum stuck in reverse.

  Sell

• BearBreaker

  Dec 14, 2025

  $SVRA Hope you didn’t bet the farm on this one.

  Sell

• TickerPhantom

  Dec 14, 2025

  $SVRA This company is making significant strides in the biopharmaceutical sector, focusing on innovative solutions for rare respiratory diseases. Its commitment to research and development positions it well in a niche market poised for growth.

  Buy

• ShortAndProud

  Dec 14, 2025

  $SVRA They're cooking up some health magic; worth keeping in the mix!

  Buy

• FUDCrusher

  Dec 13, 2025

  $SVRA Bulls reinforcing support levels.

  Buy

• StonkSlayer

  Dec 13, 2025

  $SVRA This one is the underdog in the biotech race—rooting for it feels like cheering on your favorite sports team! 🏆💊

  Buy

• CryptoCoyote

  Dec 12, 2025

  $SVRA In the unpredictable world of biotech, this company is racing against time to deliver results. The pressure from investors is intensifying, and every day counts in the quest for breakthrough treatments.

  Sell

• PortfolioPunk

  Dec 12, 2025

  $SVRA Price action tight and bullish.

  Buy

• ShortKingston

  Dec 12, 2025

  $SVRA This company’s like that one friend who always brings snacks to the party—everyone wants them around!

  Buy

• StockStrider

  Dec 11, 2025

  $SVRA Bullish channel in full motion.

  Buy

• DividendVandal

  Dec 11, 2025

  $SVRA Institutional accumulation visible.

  Buy

• FOMOKing

  Dec 11, 2025

  $SVRA Support holding perfectly — bullish reaction.

  Buy

• RiskDriver

  Dec 11, 2025

  $SVRA Oversupply overwhelming demand.

  Sell

• LiquidKnight

  Dec 11, 2025

  $SVRA Clear bullish runway ahead.

  Buy

• CapitalNova

  Dec 11, 2025

  $SVRA This clinical-stage biopharmaceutical entity is dedicated to developing innovative therapies that address serious health conditions. Their commitment to scientific research reflects a strong potential for impactful advancements in patient care.

  Buy

• CandleFreak

  Dec 10, 2025

  $SVRA This biotechnology firm is making notable strides in developing treatments for unmet medical needs. Their innovative approaches and commitment to research could lead to breakthroughs that set them apart in a highly competitive industry.

  Buy

• MarketMarauder

  Dec 10, 2025

  $SVRA Another biotech hoping for a miracle, but don't hold your breath.

  Sell

• WallStreetWolf

  Dec 9, 2025

  $SVRA This stock's potential is like a secret ingredient—it's the difference between a bland meal and a delicious feast. Don't you want the chef's special?

  Buy

• StonkZombie

  Dec 9, 2025

  $SVRA They’re cookin' up some fresh ideas in the biotech kitchen!

  Buy

• FiscalFury

  Dec 8, 2025

  $SVRA This company is working on health solutions, making it a superhero for your portfolio—cape included!

  Buy

• BuyLowBro

  Dec 8, 2025

  $SVRA This one's like a cat video on the internet: once you start watching, you can't help but be intrigued!

  Buy

• OptionOutlaw

  Dec 8, 2025

  $SVRA Savara? More like 'savor your losses.'

  Sell

• QuantumBroker

  Dec 7, 2025

  $SVRA This biotech is sitting on a potential breakthrough, but the clock is ticking! Every delay feels like a sinking ship; will they swim to success or drown under the weight of expectations?

  Sell

• StonkPhantom

  Dec 7, 2025

  $SVRA In the biotech arena, the stakes are high and the competition fierce. Breakthroughs are essential, and every day lost could mean falling behind in this race against time.

  Buy

• StockStrider

  Dec 7, 2025

  $SVRA Focused on innovative therapies, this organization is making notable progress that could disrupt traditional treatment methodologies in its field.

  Buy

• CapitalCreep

  Dec 6, 2025

  $SVRA A miracle drug? More like a miracle of marketing.

  Sell

• StonkKnight

  Dec 6, 2025

  $SVRA Low-key vibes but could flip the script real quick, keep an eye on it.

  Buy

• TraderFury

  Dec 6, 2025

  $SVRA The promise of new breakthroughs hangs in the balance, and every tiny movement in this stock sends shockwaves through the community. Can they really pull it off?

  Buy

• CapitalCreep

  Dec 5, 2025

  $SVRA Promising a revolution? More like a mediocre nap.

  Sell

• CandleCrusher

  Dec 5, 2025

  $SVRA The excitement around this company is electrifying, but can it withstand the pressure of its ambitious goals? Every day feels like a crucial turning point.

  Buy

• YieldWarden

  Dec 5, 2025

  $SVRA The pressure is building for this biotech! With clinical trials looming, the clock is ticking and the stakes couldn’t be higher. Will they break through, or is it all just smoke and mirrors?

  Sell

• BuyLowBro

  Dec 5, 2025

  $SVRA This stock might just need a little more spark to take off—like a rocket that forgot to ignite. Time for some fireworks!

  Sell

• FiscalBinary

  Dec 5, 2025

  $SVRA With their innovative therapies racing against time, this company is at a critical crossroads. Will they break through to save lives, or are they running out of steam? The pressure is building!

  Buy

• StonkKnight

  Dec 4, 2025

  $SVRA This one's got some serious potential to blow up, keep an eye on it!

  Buy

• StonkDestroyer

  Dec 4, 2025

  $SVRA Continuation pattern looks healthy.

  Buy

• YieldWarden

  Dec 4, 2025

  $SVRA Volume favors sellers overwhelmingly.

  Sell

• TheStockKnight

  Dec 4, 2025

  $SVRA Downside continuation formation.

  Sell

• BullishCraze

  Dec 4, 2025

  $SVRA Market leaning heavily bullish here.

  Buy

• MarketReaper

  Dec 4, 2025

  $SVRA They’re working on something that sounds like a potion from a wizard movie. Magic or medicine, who can tell?

  Sell

• AlphaRogue

  Dec 4, 2025

  $SVRA This company's got more life-saving tricks up its sleeves than your average superhero!

  Buy

• StonkSamurai

  Dec 3, 2025

  $SVRA Watch out, this player is making moves in the biotech space!

  Buy

• BearFighter

  Dec 3, 2025

  $SVRA Hoping for breakthroughs but stuck in mediocrity.

  Sell

• WallStreetRogue

  Dec 3, 2025

  $SVRA Emerging from clinical trials can feel like climbing a mountain. Will this company find success in a crowded space, or face the dreaded wall of setbacks?

  Buy

• MemeInvestor

  Dec 2, 2025

  $SVRA This stock's like that mysterious text from a crush; you're not quite sure what to make of it!

  Sell

• DiamondHandz

  Dec 2, 2025

  $SVRA Chillin' in the biotech lane, got the moves to stack up.

  Buy

• ChartNomad

  Dec 2, 2025

  $SVRA The race for successful treatments is intense, and every day counts. Investors are on edge, feeling the weight of uncertainty as they await results that could drastically change the game.

  Sell

• GammaSlayer

  Dec 1, 2025

  $SVRA Innovation? More like imitation in a crowded market.

  Sell

• AlgoAce

  Dec 1, 2025

  $SVRA They say good things come to those who wait. This stock must be in a waiting room with a really good magazine!

  Sell

• PaperHandsGone

  Dec 1, 2025

  $SVRA Bringing some new vibes to health, but the competition is fierce, ya dig?

  Sell

• GainsJester

  Nov 30, 2025

  $SVRA They’re making moves in biotech, potential fireworks ahead!

  Buy

• BuyLowBro

  Nov 30, 2025

  $SVRA Living life like a dog with a tennis ball, this company is always chasing big dreams and good vibes in healthcare!

  Buy

• LazyQuant

  Nov 29, 2025

  $SVRA It’s like a rollercoaster ride—thrilling, but hold on tight because it might drop when you least expect it!

  Sell

• WallStreetWolf

  Nov 29, 2025

  $SVRA Imagine if your cure for everything was just a really smart formula away. This company’s got some cool science going on that could make you feel like a superhero!

  Buy

• ShortSavage

  Nov 29, 2025

  $SVRA Innovation in the biotech world is a double-edged sword! While breakthroughs generate excitement, the pressure to succeed is overwhelming. Can they withstand the storm and deliver results that matter?

  Buy

• ShortCircuit

  Nov 29, 2025

  $SVRA Another biotech with nothing but dreams and debt.

  Sell

• BullishBerserker

  Nov 29, 2025

  $SVRA This company is on a precarious tightrope of potential breakthrough versus commercial viability! Investors are biting their nails—where will this rollercoaster take us next?

  Sell

• EquityPulse

  Nov 27, 2025

  $SVRA In the ever-evolving landscape of biopharmaceuticals, every decision can make or break a company. Are they racing ahead or falling behind?

  Buy

• TradeBlitz

  Nov 27, 2025

  $SVRA This company might just be the ultimate underdog, fighting diseases like it's a superhero movie. Get your popcorn ready! 🍿

  Buy

• StockShotz

  Nov 27, 2025

  $SVRA Imagine a superhero that saves you from bad days—this company might just have that power. Cape not included.

  Buy

• BullishBerserker

  Nov 27, 2025

  $SVRA This biotech firm is on the cusp of something big, but will their clinical trials pay off, or will they become just another statistic in the industry?

  Buy

• WallStreetGrim

  Nov 26, 2025

  $SVRA This company is exploring promising therapeutic avenues, reflecting a proactive approach in a rapidly evolving industry aimed at improving patient outcomes.

  Buy

• ChartSaber

  Nov 26, 2025

  $SVRA This one's got the vibe, feels like it's ready to pop!

  Buy

• TradeFrenzy

  Nov 26, 2025

  $SVRA Struggling to find a pulse in a dying market.

  Sell

• MarginMarauder

  Nov 26, 2025

  $SVRA Fighting respiratory issues like a superhero! Their motto must be ‘Breathe easy, we’ve got your back!’ Who wouldn’t love that?

  Buy

• OptionOverlord

  Nov 25, 2025

  $SVRA This company is like your favorite pet—adorably quirky with the potential for some amazing tricks up its sleeve!

  Buy

• ShortKingston

  Nov 25, 2025

  $SVRA Feeling a little under the weather? This company might just be the cure—let’s call it a health investment!

  Buy

• ChartCrusher

  Nov 25, 2025

  $SVRA A biotech company with more failures than wins. Pass.

  Sell

• GainsOverBrains

  Nov 25, 2025

  $SVRA On the low, but watch out, they might just blow up!

  Sell

• PaperHandsGone

  Nov 25, 2025

  $SVRA Chillin' with the innovative vibes, they’re cooking up some fresh solutions!

  Buy

• YieldSlasher

  Nov 25, 2025

  $SVRA Just another name in a sea of mediocrity.

  Sell

• ShortRaid

  Nov 25, 2025

  $SVRA This biotechnology firm is making strides in innovative therapies, with a pipeline that reflects significant promise. The focus on rare diseases could lead to impactful advancements in healthcare.

  Buy

• ChartPilot

  Nov 23, 2025

  $SVRA A pivotal moment is approaching, and the anticipation is thick. Will the breakthrough come through, or will it just be another false hope? The stakes have never been higher!

  Buy

• ChartSaber

  Nov 23, 2025

  $SVRA Struggles might be tight, watch your step here.

  Sell

• TheChartCode

  Nov 23, 2025

  $SVRA This stock has the vibe of that one friend who aces every exam without studying—totally impressive and slightly mysterious!

  Buy

• AlphaDruid

  Nov 21, 2025

  $SVRA With all the ups and downs surrounding its pipeline, it’s a wild ride! Will the next announcement propel it to greatness, or leave investors gasping for air?

  Buy

• ShortAndProud

  Nov 20, 2025

  $SVRA Makin' moves in the biotech scene, watch them rise like a boss!

  Buy

• BullishBard

  Nov 20, 2025

  $SVRA This stock might just be the superhero your portfolio needs—cape not included!

  Buy

• ChartCrusher

  Nov 20, 2025

  $SVRA This one has more setbacks than breakthroughs.

  Sell

• BullishBard

  Nov 20, 2025

  $SVRA This stock is like a superhero for lung diseases—saving the day one breathe at a time! Hero status unlocked!

  Buy

• AlphaDruid

  Nov 20, 2025

  $SVRA Amidst a whirlwind of clinical trials and investor expectations, this firm is teetering on the edge of breakthrough or breakdown. What a nail-biter!

  Buy

• TheMemeInvestor

  Nov 20, 2025

  $SVRA These folks are pushing boundaries, making some serious health moves!

  Buy

• CashMeOutside

  Nov 19, 2025

  $SVRA In the biotech game, lookin' for breakthroughs, just sayin'!

  Buy

• DiamondHands

  Nov 18, 2025

  $SVRA This company is like that friend who's always got your back, even when things get wild. Seriously, they can handle a rollercoaster like a pro!

  Buy

• MarginMarauder

  Nov 18, 2025

  $SVRA This one’s working on saving lives. It's like superhero training, but without the spandex. Who wouldn’t root for a team like that?

  Buy

• MarketWolf

  Nov 18, 2025

  $SVRA With clinical trial results just around the corner, the excitement is palpable! Could this breakthrough finally be the game-changer everyone’s been waiting for? The tension is real!

  Buy

• FiscalEngine

  Nov 17, 2025

  $SVRA Focused on developing therapies for rare diseases, this organization is revolutionizing treatment landscapes. Their dedication to research and patient-centric solutions highlights significant growth aspirations.

  Buy

• MemeInvestor

  Nov 16, 2025

  $SVRA This one feels like the underdog in a high school movie—cheering for them because they might just surprise everyone and win the big dance!

  Buy

• MarketGlitch

  Nov 15, 2025

  $SVRA Navigating the complexities of drug development is no easy task, and investors are on the edge of their seats. Can this company deliver results?

  Sell

• AlphaVandal

  Nov 14, 2025

  $SVRA Seems like a one-trick pony without the tricks.

  Sell

• WallStreetGrim

  Nov 14, 2025

  $SVRA Dedicated to developing innovative therapies, this biotech firm is setting its sights on under-addressed health issues, which could lead to significant advancements in patient care.

  Buy

• StonkSamurai

  Nov 13, 2025

  $SVRA Things are looking bright, they might just surprise you, feel me?

  Buy

• TheEquityEdge

  Nov 13, 2025

  $SVRA Focusing on novel therapies, this company is tapping into significant areas of unmet medical need, potentially leading to impactful developments in treatment options.

  Buy

• BearishBoi

  Nov 12, 2025

  $SVRA This company is like that friend who shows up unexpectedly but always brings snacks—totally worth having around!

  Buy

• PortfolioPunk

  Nov 12, 2025

  $SVRA This one feels like a cure for boredom, not a disease.

  Sell

• BearBreaker

  Nov 11, 2025

  $SVRA Another biotech that promises the moon but delivers a black hole.

  Sell

• DiamondHands

  Nov 11, 2025

  $SVRA If you think 'Savara' sounds like a fancy drink, just wait till you see their innovations—refreshing!

  Buy

• BearHunter

  Nov 10, 2025

  $SVRA They seem to be on a mission, like a superhero with a cape, ready to save the day in their sector!

  Buy

• ChartCrusher

  Nov 10, 2025

  $SVRA Another biotech fantasy that might just float away.

  Sell

• AlgoAce

  Nov 9, 2025

  $SVRA This company's vibe is like a chill beach day—relaxing yet full of unexpected waves!

  Sell

• StonkViking

  Nov 9, 2025

  $SVRA Kinda chill, but got some potential to shake things up in the neighborhood.

  Sell

• CapitalCarnage

  Nov 9, 2025

  $SVRA Innovative? Sure, if you consider hopelessness a breakthrough.

  Sell

• ProfitLancer

  Nov 9, 2025

  $SVRA This one is just chasing its tail with zero results.

  Sell

• BearFighter

  Nov 8, 2025

  $SVRA Like a mirage in the desert, looks promising but fades fast.

  Sell

• BearEater

  Nov 8, 2025

  $SVRA whoa soon-ish lower ugly wick charts tax lows hard out broken

  Sell

• PortfolioPunk

  Nov 5, 2025

  $SVRA express fire deluxe train pain dumpster

  Sell

• StonkDestroyer

  Nov 1, 2025

  $SVRA Feels like this ticker just hit its glow-up phase. Whole market's giving 'we back.

  Sell

• TradeFrenzy

  Oct 29, 2025

  $SVRA than hands? stock like weak falling faster more GPA weak my

  Sell

• AlphaHawk

  Oct 28, 2025

  $SVRA Technicals said no, emotions said yes - as usual. I'm.

  Sell

• FiscalFury

  Oct 28, 2025

  $SVRA Market drama is better than Netflix lately. If patience was a stock, I'd be rich by.

  Sell

• GainsJester

  Oct 27, 2025

  $SVRA earnings dive vol wick feels supply talking vol buzzing flows vibes levels earnings tape ouch range tax buzzing mode flows queued

  Sell

• BullishBard

  Oct 12, 2025

  $SVRA Price action smoother than my last vacation. Chart's climbing like it heard good news from.

  Sell

• DividendVortex

  Oct 10, 2025

  $SVRA gets dying bounce than sold

  Sell

• CryptoCoyote

  Oct 9, 2025

  $SVRA Rally so slow my WiFi timed out. Even my coffee is less jittery than this price action.

  Sell

• StonkSlayer

  Oct 6, 2025

  $SVRA Volume so low it's whispering sweet nothings. This chart needs therapy.

  Buy

• DividendVandal

  Oct 6, 2025

  $SVRA this my patience volume milk

  Sell

• ShortSniper

  Oct 5, 2025

  $SVRA recoveries soap a I've seen can't even fake

  Sell

• TradePulse

  Oct 4, 2025

  $SVRA volume it's rally so fake whispering low can't

  Sell

• MarketSavage

  Sep 27, 2025

  $SVRA I laughed, I cried, I averaged down anyway. The price action just.

  Sell

• BearFighter

  Sep 20, 2025

  $SVRA today trigger headfake patience money hurts hard heating soon keeping stops soon hard hedges spike maybe noise lows nasty tape smart hurts rip

  Sell

• CapitalCreep

  Sep 19, 2025

  $SVRA pain express train

  Sell

• MarginDagger

  Sep 17, 2025

  $SVRA queued risk fast here soon tape tight sentiment feels fire buzzing fast smart flows levels risk move steady today soon tape energy tape soon-ish dripping

  Buy

• BagholderElite

  Sep 16, 2025

  $SVRA noise clean dive watching liquidity maybe watching hands range dive dive dive heavy feels hard eyes buzzing wild feels now

  Sell

• TickerTrickster

  Sep 14, 2025

  $SVRA dive flows maybe macro fast session hands wick ouch loud watching hands liquidity volume today talking diamond watching smart grind level-to-level clean buzzing earnings

  Sell

• OptionRogue

  Sep 12, 2025

  $SVRA Energy in this move is contagious - someone call CNBC.

  Buy

• PnLPhantom

  Sep 11, 2025

  $SVRA owes 'ouch' stock therapy this chart me screams bills

  Buy

• ProfitGremlin

  Sep 5, 2025

  $SVRA just bear this cave dip

  Buy

• StonkViking

  Aug 29, 2025

  $SVRA Even my coffee is less jittery than this price action.

  Buy

• TheEarningsBeast

  Aug 28, 2025

  $SVRA Vibes are bullish and my coffee agrees. This chart looks like it just had an.

  Sell

• AlphaVandal

  Aug 24, 2025

  $SVRA Momentum so clean I'd frame this chart. This volume deserves a standing ovation.

  Sell

• CandleFreak

  Aug 21, 2025

  $SVRA green is dumpster allergic fire candles price action deluxe to

  Sell

• LazyQuant

  Aug 17, 2025

  $SVRA owes me therapy this bills stock

  Sell

• YieldHunter

  Aug 11, 2025

  $SVRA The price action just ghosted resistance again. This chart's more.

  Sell

• YOLOTrader

  Aug 11, 2025

  $SVRA Trend so clean even my chart indicators are blushing. This rally just cured my.

  Buy

• TradeReckoner

  Aug 11, 2025

  $SVRA bear earnings earnings ugly bagholder here tape mode tax trap money volume frankly

  Sell

• CashKiller

  Aug 11, 2025

  $SVRA Volatility got me questioning my life choices again. Someone please unplug the algos.

  Buy

• DigitalDividend

  Jun 11, 2025

  $SVRA broken hard dead rip today liquidity sentiment frankly range cat weak on

  Sell

• PortfolioFreak

  May 30, 2025

  $SVRA hands look clean nasty trap ugly doom heavy smart risk heating choppy stops volume

  Sell

• CapitalHex

  Apr 20, 2025

  $SVRA money choppy rough supply nasty queued now hands liquidity look

  Sell

• BullRunBoss

  Feb 7, 2025

  $SVRA vibes volume levels maybe vol hedges today earnings city heating dive rough money buzzing tbh steady hands keeping

  Sell

• FiscalEngine

  Nov 18, 2024

  $SVRA heavy nasty today fast vibes hard it headfake it cliff sentiment tape clear broken frankly hedges level-to-level imo choppy

  Sell

• CapitalFrame

  Oct 8, 2024

  $SVRA nimble queued bagholder talking money no wall trend rip hands on dive nasty smart headfake today nasty

  Sell

• FOMOKing

  Aug 13, 2024

  $SVRA on talking clear momentum nimble clean breakout vibes noise smooth rocket sentiment soon level-to-level imo

  Buy

• VolatilityStrike

  Jul 31, 2024

  $SVRA diamond headfake dive tax hurts nimble mode dive dive clear hedges tbh trap liquidity energy now

  Sell

• MarketPulseX

  Jun 22, 2024

  $SVRA fading levels here nasty ouch risk queued heavy watching charts range humming ruggy earnings cat hard here spike

  Sell

• ChartCrusher

  Jun 4, 2024

  $SVRA buzzing whoa tape out ruggy my eyes weak humming dead wall my whoa

  Sell

• CapitalNova

  May 29, 2024

  $SVRA today eyes broken tight trigger dead tight candle sauce today trend

  Sell

• TradePredator

  May 11, 2024

  $SVRA ugly rough nimble maybe ugly choppy dive whoa mode hedges doom mess level-to-level

  Sell

• YieldHunter

  Apr 22, 2024

  $SVRA levels dive session session ugly feels supply lower dumping tape

  Sell

• StonkViking

  Apr 8, 2024

  $SVRA momentum clear printing levels nimble vibes now passed talking clean maybe talking bull nasty soon smart alpha mode range

  Buy

• RiskRaider

  Mar 27, 2024

  $SVRA theta now today risk talking watching lower range fast my broken cat heavy candle weak

  Sell

• QuantRift

  Mar 23, 2024

  $SVRA heavy range feels today soon vibes patience vibes heavy breakout smooth sentiment hedges

  Buy